{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:10:23Z","timestamp":1792062623679,"version":"4.4.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,9,10]],"date-time":"2010-09-10T00:00:00Z","timestamp":1284076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s11940-010-0095-4","type":"journal-article","created":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T06:59:09Z","timestamp":1284015549000},"page":"539-561","source":"Crossref","is-referenced-by-count":97,"title":["Treatment of Tics and Tourette Syndrome"],"prefix":"10.1007","volume":"12","author":[{"given":"Harvey S.","family":"Singer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,10]]},"reference":[{"key":"95_CR1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(05)01012-4","volume":"4","author":"HS Singer","year":"2005","unstructured":"Singer HS: Tourette\u2019s syndrome: from behaviour to biology. Lancet Neurol 2005, 4:149\u2013159.","journal-title":"Lancet Neurol"},{"key":"95_CR2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/da.20711","volume":"27","author":"JT Walkup","year":"2010","unstructured":"Walkup JT, Ferrao Y, Leckman JF, et al.: Tic disorders: some key issues for DSM-V. Depress Anxiety 2010, 27:600\u2013610.","journal-title":"Depress Anxiety"},{"key":"95_CR3","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1111\/j.1651-2227.2005.tb01837.x","volume":"94","author":"N Khalifa","year":"2005","unstructured":"Khalifa N, von Knorring AL: Tourette syndrome and other tic disorders in a total population of children: clinical assessment and background. Acta Paediatr 2005, 94:1608\u20131614.","journal-title":"Acta Paediatr"},{"key":"95_CR4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1212\/WNL.59.3.414","volume":"59","author":"R Kurlan","year":"2002","unstructured":"Kurlan R, Como PG, Miller B, et al.: The behavioral spectrum of tic disorders: a community-based study. Neurology 2002, 59:414\u2013420.","journal-title":"Neurology"},{"key":"95_CR5","first-page":"191","volume":"8","author":"AE Cavanna","year":"2009","unstructured":"Cavanna AE, Eddy C, Rickards HE: Cognitive functioning in Tourette syndrome. Discov Med 2009, 8:191\u2013195.","journal-title":"Discov Med"},{"key":"95_CR6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1469-8749.2008.03168.x","volume":"51","author":"T Pringsheim","year":"2009","unstructured":"Pringsheim T, Lang A, Kurlan R, et al.: Understanding disability in Tourette syndrome. Dev Med Child Neurol 2009, 51:468\u2013472.","journal-title":"Dev Med Child Neurol"},{"key":"95_CR7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1590\/S1516-44462005000100006","volume":"27","author":"NI Mejia","year":"2005","unstructured":"Mejia NI, Jankovic J: Secondary tics and tourettism. Rev Bras Psiquiatr 2005, 27:11\u201317.","journal-title":"Rev Bras Psiquiatr"},{"key":"95_CR8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0887-8994(97)00200-2","volume":"18","author":"A Bergin","year":"1998","unstructured":"Bergin A, Waranch HR, Brown J, et al.: Relaxation therapy in Tourette syndrome: a pilot study. Pediatr Neurol 1998, 18:136\u2013142.","journal-title":"Pediatr Neurol"},{"key":"95_CR9","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.brat.2009.07.021","volume":"47","author":"KP O\u2019Connor","year":"2009","unstructured":"O\u2019Connor KP, Laverdure A, Taillon A, et al.: Cognitive behavioral management of Tourette\u2019s syndrome and chronic tic disorder in medicated and unmedicated samples. Behav Res Ther 2009, 47:1090\u20131095.","journal-title":"Behav Res Ther"},{"key":"95_CR10","volume-title":"Managing Tourette Syndrome: A Behavioral Intervention for Children and Adults","author":"DW Woods","year":"2008","unstructured":"Woods DW, Piacentini JC, Chang SW, et al.: Managing Tourette Syndrome: A Behavioral Intervention for Children and Adults. New York: Oxford University Press; 2008. Woods DW, Piacentini JC, Chang SW, et al.: Managing Tourette Syndrome: A Behavioral Intervention for Children and Adults. New York: Oxford University Press; 2008."},{"key":"95_CR11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/08830738060210080101","volume":"21","author":"MB Himle","year":"2006","unstructured":"Himle MB, Woods DW, Piacentini JC, Walkup JT: Brief review of habit reversal training for Tourette syndrome. J Child Neurol 2006, 21:719\u2013725.","journal-title":"J Child Neurol"},{"key":"95_CR12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.brat.2005.08.007","volume":"44","author":"T Deckersbach","year":"2006","unstructured":"Deckersbach T, Rauch S, Buhlmann U, Wilhelm S: Habit reversal versus supportive psychotherapy in Tourette\u2019s disorder: a randomized controlled trial and predictors of treatment response. Behav Res Ther 2006, 44:1079\u20131090.","journal-title":"Behav Res Ther"},{"key":"95_CR13","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.2010.607","volume":"303","author":"J Piacentini","year":"2010","unstructured":"Piacentini J, Woods DW, Scahill L, et al.: Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA 2010, 303:1929\u20131937.","journal-title":"JAMA"},{"key":"95_CR14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1157\/13129113","volume":"131","author":"R Garcia-Lopez","year":"2008","unstructured":"Garcia-Lopez R, Romero-Gonzalez J, Perea-Milla E, et al.: [An open study evaluating the efficacy and security of magnesium and vitamin B(6) as a treatment of Tourette syndrome in children.]. Med Clin (Barc) 2008, 131:689\u2013692.","journal-title":"Med Clin (Barc)"},{"key":"95_CR15","first-page":"392","volume":"26","author":"S Ma","year":"2006","unstructured":"Ma S, Liu XY, Yu RL, Chen LJ: [Clinical observation on acupuncture for treatment of Tourette\u2019s syndrome]. Zhongguo Zhen Jiu 2006, 26:392\u2013394.","journal-title":"Zhongguo Zhen Jiu"},{"key":"95_CR16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S1461145705005729","volume":"9","author":"A Mantovani","year":"2006","unstructured":"Mantovani A, Lisanby SH, Pieraccini F, et al.: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette\u2019s syndrome (TS). Int J Neuropsychopharmacol 2006, 9:95\u2013100.","journal-title":"Int J Neuropsychopharmacol"},{"key":"95_CR17","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.clinph.2007.07.011","volume":"118","author":"A Mantovani","year":"2007","unstructured":"Mantovani A, Leckman JF, Grantz H, et al.: Repetitive transcranial magnetic stimulation of the supplementary motor area in the treatment of Tourette syndrome: report of two cases. Clin Neurophysiol 2007, 118:2314\u20132315.","journal-title":"Clin Neurophysiol"},{"key":"95_CR18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.nurx.2006.01.009","volume":"3","author":"L Scahill","year":"2006","unstructured":"Scahill L, Erenberg G, Berlin CM Jr, et al.: Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006, 3:192\u2013206.","journal-title":"NeuroRx"},{"key":"95_CR19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","volume":"58","author":"Tourette\u2019s Syndrome Study Group","year":"2002","unstructured":"Tourette's Syndrome Study Group: Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002, 58:527\u2013536.","journal-title":"Neurology"},{"key":"95_CR20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.pediatrneurol.2008.12.014","volume":"40","author":"EF Hedderick","year":"2009","unstructured":"Hedderick EF, Morris CM, Singer HS: Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 2009, 40:420\u2013425.","journal-title":"Pediatr Neurol"},{"key":"95_CR21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004583-200203000-00013","volume":"41","author":"GR Gaffney","year":"2002","unstructured":"Gaffney GR, Perry PJ, Lund BC, et al.: Risperidone versus clonidine in the treatment of children and adolescents with Tourette\u2019s syndrome. J Am Acad Child Adolesc Psychiatry 2002, 41:330\u2013336.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"95_CR22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/00048670802277222","volume":"42","author":"YS Du","year":"2008","unstructured":"Du YS, Li HF, Vance A, et al.: Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust NZ J Psychiatry 2008, 42:807\u2013813.","journal-title":"Aust NZ J Psychiatry"},{"key":"95_CR23","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/CHI.0b013e3181b26e9f","volume":"48","author":"MH Bloch","year":"2009","unstructured":"Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF: Meta-analysis: treatment of attention-deficit\/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009, 48:884\u2013893.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"95_CR24","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","volume":"158","author":"L Scahill","year":"2001","unstructured":"Scahill L, Chappell PB, Kim YS, et al.: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001, 158:1067\u20131074.","journal-title":"Am J Psychiatry"},{"key":"95_CR25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00002826-200211000-00009","volume":"25","author":"DD Cummings","year":"2002","unstructured":"Cummings DD, Singer HS, Krieger M, et al.: Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 2002, 25:325\u2013332.","journal-title":"Clin Neuropharmacol"},{"key":"95_CR26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.158.6.968","volume":"158","author":"FS Abuzzahab","year":"2001","unstructured":"Abuzzahab FS, Brown VL: Control of Tourette\u2019s syndrome with topiramate. Am J Psychiatry 2001, 158:968.","journal-title":"Am J Psychiatry"},{"key":"95_CR27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/WNF.0b013e3181c295c1","volume":"33","author":"SH Kuo","year":"2010","unstructured":"Kuo SH, Jimenez-Shahed J: Topiramate in treatment of Tourette syndrome. Clin Neuropharmacol 2010, 33:32\u201334.","journal-title":"Clin Neuropharmacol"},{"key":"95_CR28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","volume":"81","author":"J Jankovic","year":"2009","unstructured":"Jankovic J, Jimenez-Shahed J, Brown LW: A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2009, 81:70\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"95_CR29","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/mds.20385","volume":"20","author":"Y Awaad","year":"2005","unstructured":"Awaad Y, Michon AM, Minarik S: Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 2005, 20:714\u2013718.","journal-title":"Mov Disord"},{"key":"95_CR30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ejpn.2008.12.006","volume":"13","author":"A Fernandez-Jaen","year":"2009","unstructured":"Fernandez-Jaen A, Fernandez-Mayoralas DM, Munoz-Jareno N, Calleja-Perez B: An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. Eur J Paediatr Neurol 2009, 13:541\u2013545.","journal-title":"Eur J Paediatr Neurol"},{"key":"95_CR31","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/mds.21615","volume":"22","author":"CL Smith-Hicks","year":"2007","unstructured":"Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS: A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 2007, 22:1764\u20131770.","journal-title":"Mov Disord"},{"key":"95_CR32","volume-title":"Gilles de la Tourette Syndrome","author":"AK Shapiro","year":"1988","unstructured":"Shapiro AK: Gilles de la Tourette Syndrome. New York: Raven; 1988."},{"key":"95_CR33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/088307389901400508","volume":"14","author":"Y Awaad","year":"1999","unstructured":"Awaad Y: Tics in Tourette syndrome: new treatment options. J Child Neurol 1999, 14:316\u2013319.","journal-title":"J Child Neurol"},{"key":"95_CR34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1212\/WNL.56.5.599","volume":"56","author":"HS Singer","year":"2001","unstructured":"Singer HS, Wendlandt J, Krieger M, Giuliano J: Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 2001, 56:599\u2013604.","journal-title":"Neurology"},{"key":"95_CR35","first-page":"296","volume":"35","author":"I Drtilkova","year":"1994","unstructured":"Drtilkova I, Balaotkova B, Lemanova H, Zak J: Therapeutical effects of clonidine and clonazepam in children with tic syndrome. Homeost Health Dis 1994, 35:296.","journal-title":"Homeost Health Dis"},{"key":"95_CR36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","volume":"360","author":"WA Ray","year":"2009","unstructured":"Ray WA, Chung CP, Murray KT, et al.: Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225\u2013235.","journal-title":"N Engl J Med"},{"key":"95_CR37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1056\/NEJMe0809417","volume":"360","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Avorn J: Antipsychotic agents and sudden cardiac death\u2014How should we manage the risk? N Engl J Med 2009, 360:294\u2013296.","journal-title":"N Engl J Med"},{"key":"95_CR38","doi-asserted-by":"crossref","unstructured":"Pringsheim T, Marras C: Pimozide for tics in Tourette\u2019s syndrome. Cochrane Database Syst Rev 2009, CD006996. This comprehensive review of prior studies assessed the benefits and risks of pimozide in comparison to placebo or other medications in treating tics in Tourette syndrome.","DOI":"10.1002\/14651858.CD006996.pub2"},{"key":"95_CR39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000120222","volume":"12","author":"HS Singer","year":"1985","unstructured":"Singer HS, Gammon K, Quaskey S: Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1985, 12:71\u201374.","journal-title":"Pediatr Neurosci"},{"key":"95_CR40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/archneur.1984.04050150049015","volume":"41","author":"CG Goetz","year":"1984","unstructured":"Goetz CG, Tanner CM, Klawans HL: Fluphenazine and multifocal tic disorders. Arch Neurol 1984, 41:271\u2013272.","journal-title":"Arch Neurol"},{"key":"95_CR41","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S1474-4422(09)70183-8","volume":"8","author":"J Jankovic","year":"2009","unstructured":"Jankovic J: Treatment of hyperkinetic movement disorders. Lancet Neurol 2009, 8:844\u2013856.","journal-title":"Lancet Neurol"},{"key":"95_CR42","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","volume":"46","author":"E Shapiro","year":"1989","unstructured":"Shapiro E, Shapiro AK, Fulop G, et al.: Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette\u2019s syndrome. Arch Gen Psychiatry 1989, 46:722\u2013730.","journal-title":"Arch Gen Psychiatry"},{"key":"95_CR43","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L, Leckman JF, Schultz RT, et al.: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60:1130\u20131135.","journal-title":"Neurology"},{"key":"95_CR44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","volume":"22","author":"Y Dion","year":"2002","unstructured":"Dion Y, Annable L, Sandor P, Chouinard G: Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002, 22:31\u201339.","journal-title":"J Clin Psychopharmacol"},{"key":"95_CR45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4088\/JCP.v62n0111","volume":"62","author":"R Bruggeman","year":"2001","unstructured":"Bruggeman R, van der Linden C, Buitelaar JK, et al.: Risperidone versus pimozide in Tourette\u2019s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001, 62:50\u201356.","journal-title":"J Clin Psychiatry"},{"key":"95_CR46","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004583-200402000-00017","volume":"43","author":"DL Gilbert","year":"2004","unstructured":"Gilbert DL, Batterson JR, Sethuraman G, Sallee FR: Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004, 43:206\u2013214.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"95_CR47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/cap.2007.061","volume":"18","author":"C Budman","year":"2008","unstructured":"Budman C, Coffey BJ, Shechter R, et al.: Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008, 18:509\u2013515.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"95_CR48","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1176\/appi.neuropsych.21.2.224","volume":"21","author":"W Kawohl","year":"2009","unstructured":"Kawohl W, Schneider F, Vernaleken I, Neuner I: Chronic motor tic disorder and aripiprazole. J Neuropsychiatry Clin Neurosci 2009, 21:224.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"95_CR49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1089\/cap.2008.0149","volume":"19","author":"TK Murphy","year":"2009","unstructured":"Murphy TK, Mutch PJ, Reid JM, et al.: Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol 2009, 19:441\u2013447.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"95_CR50","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hup.798","volume":"21","author":"L Davies","year":"2006","unstructured":"Davies L, Stern JS, Agrawal N, Robertson MM: A case series of patients with Tourette\u2019s syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006, 21:447\u2013453.","journal-title":"Hum Psychopharmacol"},{"key":"95_CR51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/cap.2007.0064","volume":"18","author":"WS Seo","year":"2008","unstructured":"Seo WS, Sung HM, Sea HS, Bai DS: Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 2008, 18:197\u2013205.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"95_CR52","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","volume":"39","author":"FR Sallee","year":"2000","unstructured":"Sallee FR, Kurlan R, Goetz CG, et al.: Ziprasidone treatment of children and adolescents with Tourette\u2019s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000, 39:292\u2013299.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"95_CR53","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/JCP.0b013e3181c06dad","volume":"29","author":"G Willmund","year":"2009","unstructured":"Willmund G, Lee AH, Wertenauer F, et al.: Vocal tics associated with ziprasidone. J Clin Psychopharmacol 2009, 29:611\u2013612.","journal-title":"J Clin Psychopharmacol"},{"key":"95_CR54","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4088\/JCP.v62n0412","volume":"62","author":"CL Budman","year":"2001","unstructured":"Budman CL, Gayer A, Lesser M, et al.: An open-label study of the treatment efficacy of olanzapine for Tourette\u2019s disorder. J Clin Psychiatry 2001, 62:290\u2013294.","journal-title":"J Clin Psychiatry"},{"key":"95_CR55","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/cap.2007.135","volume":"18","author":"JT McCracken","year":"2008","unstructured":"McCracken JT, Suddath R, Chang S, et al.: Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 2008, 18:501\u2013508.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"95_CR56","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s004150070173","volume":"247","author":"M Onofrj","year":"2000","unstructured":"Onofrj M, Paci C, D\u2019Andreamatteo G, Toma L: Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 2000, 247:443\u2013446.","journal-title":"J Neurol"},{"key":"95_CR57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/104454603322572624","volume":"13","author":"NM Mukaddes","year":"2003","unstructured":"Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette\u2019s disorder. J Child Adolesc Psychopharmacol 2003, 13:295\u2013299.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"95_CR58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00044011-200727020-00005","volume":"27","author":"M Copur","year":"2007","unstructured":"Copur M, Arpaci B, Demir T, Narin H: Clinical effectiveness of quetiapine in children and adolescents with Tourette\u2019s syndrome: a retrospective case-note survey. Clin Drug Investig 2007, 27:123\u2013130.","journal-title":"Clin Drug Investig"},{"key":"95_CR59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","volume":"22","author":"C Kenney","year":"2007","unstructured":"Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007, 22:193\u2013197.","journal-title":"Mov Disord"},{"key":"95_CR60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mds.21161","volume":"22","author":"C Kenney","year":"2007","unstructured":"Kenney C, Hunter C, Davidson A, Jankovic J: Short-term effects of tetrabenazine on chorea associated with Huntington\u2019s disease. Mov Disord 2007, 22:10\u201313.","journal-title":"Mov Disord"},{"key":"95_CR61","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00044011-200828070-00006","volume":"28","author":"M Porta","year":"2008","unstructured":"Porta M, Sassi M, Cavallazzi M, et al.: Tourette\u2019s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig 2008, 28:443\u2013459.","journal-title":"Clin Drug Investig"},{"key":"95_CR62","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A, et al.: Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699\u20131706.","journal-title":"Neurology"},{"key":"95_CR63","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1212\/WNL.56.5.605","volume":"56","author":"C Marras","year":"2001","unstructured":"Marras C, Andrews D, Sime E, Lang AE: Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001, 56:605\u2013610.","journal-title":"Neurology"},{"key":"95_CR64","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","volume":"57","author":"CH Kwak","year":"2000","unstructured":"Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol 2000, 57:1190\u20131193.","journal-title":"Arch Neurol"},{"key":"95_CR65","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.parkreldis.2009.11.011","volume":"16","author":"JJ Rath","year":"2010","unstructured":"Rath JJ, Tavy DL, Wertenbroek AA, et al.: Botulinum toxin type A in simple motor tics: short-term and long-term treatment-effects. Parkinsonism Relat Disord 2010, 16:478\u2013481.","journal-title":"Parkinsonism Relat Disord"},{"key":"95_CR66","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10072-003-0201-4","volume":"24","author":"M Porta","year":"2004","unstructured":"Porta M, Maggioni G, Ottaviani F, Schindler A: Treatment of phonic tics in patients with Tourette\u2019s syndrome using botulinum toxin type A. Neurol Sci 2004, 24:420\u2013423.","journal-title":"Neurol Sci"},{"key":"95_CR67","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00002826-199006000-00005","volume":"13","author":"MM Robertson","year":"1990","unstructured":"Robertson MM, Schnieden V, Lees AJ: Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 1990, 13:229\u2013235.","journal-title":"Clin Neuropharmacol"},{"key":"95_CR68","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0929-6646(09)60406-X","volume":"108","author":"CS Ho","year":"2009","unstructured":"Ho CS, Chen HJ, Chiu NC, et al.: Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc 2009, 108:788\u2013793.","journal-title":"J Formos Med Assoc"},{"key":"95_CR69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00449911","volume":"237","author":"C Eggers","year":"1988","unstructured":"Eggers C, Rothenberger A, Berghaus U: Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 1988, 237:223\u2013229.","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"95_CR70","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","volume":"64","author":"KR Muller-Vahl","year":"2003","unstructured":"Muller-Vahl KR, Schneider U, Prevedel H, et al.: Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003, 64:459\u2013465.","journal-title":"J Clin Psychiatry"},{"key":"95_CR71","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.mehy.2009.11.028","volume":"74","author":"HS Singer","year":"2010","unstructured":"Singer HS, Morris C, Grados M: Glutamatergic modulatory therapy for Tourette syndrome. Med Hypotheses 2010, 74:862\u2013867.","journal-title":"Med Hypotheses"},{"key":"95_CR72","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clinthera.2008.01.010","volume":"30","author":"E Cubo","year":"2008","unstructured":"Cubo E, Fernandez Jaen A, Moreno C, et al.: Donepezil use in children and adolescents with tics and attention-deficit\/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther 2008, 30:182\u2013189.","journal-title":"Clin Ther"},{"key":"95_CR73","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1176\/appi.ajp.2007.07060978","volume":"164","author":"M Bortolato","year":"2007","unstructured":"Bortolato M, Muroni A, Marrosu F: Treatment of Tourette\u2019s syndrome with finasteride. Am J Psychiatry 2007, 164:1914\u20131915.","journal-title":"Am J Psychiatry"},{"key":"95_CR74","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00004714-199808000-00013","volume":"18","author":"BS Peterson","year":"1998","unstructured":"Peterson BS, Zhang H, Anderson GM, Leckman JF: A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette\u2019s syndrome. J Clin Psychopharmacol 1998, 18:324\u2013331.","journal-title":"J Clin Psychopharmacol"},{"key":"95_CR75","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4088\/JCP.v66n0413","volume":"66","author":"P Toren","year":"2005","unstructured":"Toren P, Weizman A, Ratner S, et al.: Ondansetron treatment in Tourette\u2019s disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2005, 66:499\u2013503.","journal-title":"J Clin Psychiatry"},{"key":"95_CR76","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1176\/ajp.156.7.1122a","volume":"156","author":"C Bonnier","year":"1999","unstructured":"Bonnier C, Nassogne MC, Evrard P: Ketanserin treatment of Tourette\u2019s syndrome in children. Am J Psychiatry 1999, 156:1122\u20131123.","journal-title":"Am J Psychiatry"},{"key":"95_CR77","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(98)12297-3","volume":"354","author":"SJ Perlmutter","year":"1999","unstructured":"Perlmutter SJ, Leitman SF, Garvey MA, et al.: Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999, 354:1153\u20131158.","journal-title":"Lancet"},{"key":"95_CR78","doi-asserted-by":"crossref","first-page":"537","DOI":"10.4088\/JCP.v65n0413","volume":"65","author":"PJ Hoekstra","year":"2004","unstructured":"Hoekstra PJ, Minderaa RB, Kallenberg CG: Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. J Clin Psychiatry 2004, 65:537\u2013542.","journal-title":"J Clin Psychiatry"},{"key":"95_CR79","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/08830738060210080301","volume":"21","author":"JS Neimat","year":"2006","unstructured":"Neimat JS, Patil PG, Lozano AM: Novel surgical therapies for Tourette syndrome. J Child Neurol 2006, 21:715\u2013718.","journal-title":"J Child Neurol"},{"key":"95_CR80","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jpsychores.2009.06.001","volume":"67","author":"M Porta","year":"2009","unstructured":"Porta M, Sassi M, Ali F, et al.: Neurosurgical treatment for Gilles de la Tourette syndrome: the Italian perspective. J Psychosom Res 2009, 67:585\u2013590.","journal-title":"J Psychosom Res"},{"key":"95_CR81","first-page":"72","volume":"1","author":"JW Mink","year":"2009","unstructured":"Mink JW: Clinical review of DBS for Tourette syndrome. Front Biosci (Elite Ed) 2009, 1:72\u201376.","journal-title":"Front Biosci (Elite Ed)"},{"key":"95_CR82","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/archneur.65.7.952","volume":"65","author":"ML Welter","year":"2008","unstructured":"Mink JW: Clinical review of DBS for Tourette syndrome. Front Biosci (Elite Ed) 2009, 1:72\u201376.","journal-title":"Arch Neurol"},{"key":"95_CR83","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000112429","volume":"86","author":"DC Shields","year":"2008","unstructured":"Shields DC, Cheng ML, Flaherty AW, et al.: Microelectrode-guided deep brain stimulation for Tourette syndrome: within-subject comparison of different stimulation sites. Stereotact Funct Neurosurg 2008, 86:87\u201391.","journal-title":"Stereotact Funct Neurosurg"},{"key":"95_CR84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mds.10649","volume":"19","author":"Y Temel","year":"2004","unstructured":"Temel Y, Visser-Vandewalle V: Surgery in Tourette syndrome. Mov Disord 2004, 19:3\u201314.","journal-title":"Surgery in Tourette syndrome. Mov Disord"},{"key":"95_CR85","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1017\/S0012162206001290","volume":"48","author":"V Roessner","year":"2006","unstructured":"Roessner V, Robatzek M, Knapp G, et al.: First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol 2006, 48:616\u2013621.","journal-title":"Dev Med Child Neurol"},{"key":"95_CR86","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.spen.2005.12.003","volume":"12","author":"G Erenberg","year":"2005","unstructured":"Erenberg G: The relationship between Tourette syndrome, attention deficit hyperactivity disorder, and stimulant medication: a critical review. Semin Pediatr Neurol 2005, 12:217\u2013221.","journal-title":"Semin Pediatr Neurol"},{"key":"95_CR87","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000188869.58300.a7","volume":"65","author":"AJ Allen","year":"2005","unstructured":"Allen AJ, Kurlan RM, Gilbert DL, et al.: Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005, 65:1941\u20131949.","journal-title":"Neurology"},{"key":"95_CR88","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1542\/peds.95.1.74","volume":"95","author":"HS Singer","year":"1995","unstructured":"Singer HS, Brown J, Quaskey S, et al.: The treatment of attention-deficit hyperactivity disorder in Tourette\u2019s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995, 95:74\u201381.","journal-title":"Pediatrics"},{"key":"95_CR89","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archpsyc.59.7.649","volume":"59","author":"T Spencer","year":"2002","unstructured":"Spencer T, Biederman J, Coffey B, et al.: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit\/hyperactivity disorder. Arch Gen Psychiatry 2002, 59:649\u2013656.","journal-title":"Arch Gen Psychiatry"},{"key":"95_CR90","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1521\/bumc.2010.74.2.167","volume":"74","author":"EA Storch","year":"2010","unstructured":"Storch EA, Bjorgvinsson T, Riemann B, et al.: Factors associated with poor response in cognitive-behavioral therapy for pediatric obsessive-compulsive disorder. Bull Menninger Clin 2010, 74:167\u2013185.","journal-title":"Bull Menninger Clin"},{"key":"95_CR91","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/NDT.S3149","volume":"6","author":"EH Decloedt","year":"2010","unstructured":"Decloedt EH, Stein DJ: Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat 2010, 6:233\u2013242.","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-010-0095-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-010-0095-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-010-0095-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T06:52:58Z","timestamp":1685775178000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-010-0095-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,10]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["95"],"URL":"https:\/\/doi.org\/10.1007\/s11940-010-0095-4","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,10]]}}}